摘要
目的 研究雷珠单抗联合视网膜激光光凝治疗青年增殖型糖尿病视网膜病变(PDR)的疗效及安全性。方法 选取2019年5月至2021年1月的青年PDR患者64例,随机分为对照组和观察组,每组32例。对照组单纯予以视网膜激光光凝治疗,观察组基于对照组条件联合雷珠单抗用药,比较2组不同治疗阶段的最佳矫正视力(BCVA)、视网膜厚度以及并发症发生情况。结果 治疗前,2组的BCVA、视网膜厚度比较,差异无统计学意义(P>0.05);治疗后1、3个月,观察组的BCVA、视网膜厚度均低于对照组,差异有统计学意义(P<0.05)。治疗前,2组患者LogMAR视力及视野灰度值比较,差异无统计学意义(P>0.05);治疗后,观察组的LogMAR视力及视野灰度值均低于对照组(P<0.05)。观察组并发症发生率与对照组的比较,差异无统计学意义(P>0.05)。结论 雷珠单抗+视网膜激光光凝疗法能够明显改善青年PDR患者的视力,并保障治疗的安全性。
Objective To investigate the efficacy and safety of Leizumab combined with retinal laser photocoagulation(RLP) on proliferative diabetic retinopathy(PDR) in young adults.Methods A total of 64 young PDR patients admitted to our hospital from May 2019 to January 2021 were randomly divided into two groups, 32 patients in each group. The observation group was given Leizumab + RLP, while the control group was given the latter alone. The key observation was the best-corrected visual acuity(BCVA), retinal thickness and complications between groups during different stages.Results There was no significant difference in BCVA and retinal thickness before treatment between groups(P> 0.05), but the above indicators on months 1 and 3 were significantly lower in the observation group than the control group(P<0.05). There was no significant difference in LogMAR visual acuity(VA) and visual field gray value between groups(P> 0.05), the above indicators were lower in the observation group than the control group after treatment(P<0.05). There was no significant difference in complication rates between the two groups(P>0.05).Conclusion For young adults with PDR, Leizumab combined with RLP can significantly improve VA, with the safety of treatment.
作者
王冬艳
王丽英
杨娜
莫负华
黄磊
张月玲
WANG Dongyan;WANG Liying;YANG Na(Department of Ophthalmology,Baoding First Central Hospital,Hebei,Baoding 071000,China)
出处
《河北医药》
CAS
2022年第23期3630-3632,共3页
Hebei Medical Journal
基金
保定市科技计划项目(编号:1941ZF046)。
关键词
雷珠单抗
视网膜激光光凝
增值型糖尿病视网膜病变
疗效
安全性
leizumab
retinal laser photocoagulation
proliferative diabetic retinopathy
curative effect
security
